Tenax Therapeutics Inc (TENX) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Tenax Therapeutics Inc $3.11, price $1.98, upside +57.1%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Tenax Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $1.38 – $3,312 · fair‑value band $2.06 – $3.89 · the $1.98 price screens below the $3.11 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Tenax Therapeutics in your weekly email
Every Wednesday you see whether Tenax Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Show more
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Stock analysis
Tenax Therapeutics Inc (TENX) currently trades at $1.98, while our model-based Fair Value estimate is $3.11, implying the stock looks roughly 36.4% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $2.06 (bear) to $3.89 (bull), the price of $1.98 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Tenax Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$52.6M in FY2025.
Key figures
Market cap $325M · EPS (TTM) $−1.41 · Return on equity −51.7% · Return on assets (EBIT) −203% · Free cash flow −$35.8M · Net cash $97.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 89% below its 52-week high and 44% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 57%, TENX screens cheaper than that median.
Fair Value models
Bear $2.06Fair Value $3.11Bull $3.89
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−44.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.3%
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+88.8%
’98
’99
’00
’01
’09
’10
’11
’12
’13
’14
’15
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,276.8% (2010) → −31,729.6% (2015)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score36 · Below median
Fair Value upside+61.2% · Top 25%
Profitability
Return on assets−32.7% · Bottom 25%
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth0.0% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Tenax Therapeutics Inc (TENX) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $3.11 versus a price of $1.98, about +57% upside (undervalued).
What is the fair value of TENX?
Our model-based fair value for Tenax Therapeutics Inc is $3.11 (as of Sep 27, 2026), built from audited fundamentals. The current price: $1.98.
What is the quality score of TENX?
Tenax Therapeutics Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tenax Therapeutics Inc (TENX)?
Our model-based price target is the fair value of $3.11 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $2.06, optimistic scenario $3.89. It is a calculation from audited fundamentals, not an analyst target.
What is the Tenax Therapeutics Inc stock forecast for 2026?
Our models put fair value at $3.11, about +57% upside versus a price of $1.98 (undervalued). Cautious scenario $2.06, optimistic scenario $3.89. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Tenax Therapeutics Inc (TENX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tenax Therapeutics Inc it is $3.11 per share (as of Sep 27, 2026), against a price of $1.98. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Tenax Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, TENX trades below its calculated fair value: price $1.98, fair value $3.11, a gap of about +57% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TENX?
No. The price is what the market pays today ($1.98); the fair value is what the company's own numbers justify ($3.11). For Tenax Therapeutics Inc the two are $1.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tenax Therapeutics Inc worth?
The market values Tenax Therapeutics Inc at about $325M (market capitalisation, as of Sep 27, 2026). Per share that is $1.98; our models calculate a fair value of $3.11 per share.
What do the bullish and bearish scenarios say about TENX?
Our models span a range for Tenax Therapeutics Inc: cautious scenario $2.06, base $3.11, optimistic $3.89 per share (as of Sep 27, 2026, price $1.98). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of TENX?
The PEG ratio of Tenax Therapeutics Inc is 1.44 (P/E divided by earnings growth, as of Sep 27, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Tenax Therapeutics Inc (TENX)?
Balance-sheet figures for Tenax Therapeutics Inc (as of Sep 27, 2026): return on equity −51.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is TENX from its 52-week high?
Tenax Therapeutics Inc trades at $1.98, about 89% below its 52-week high of $18.32 and 44% above the low of $1.38 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $3.11 is for.
Which stocks are comparable to Tenax Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tenax Therapeutics Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $1.98, calculated fair value $3.11 (+57%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TENX calculated?
We run Tenax Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.11, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Tenax Therapeutics Inc currently trades 36 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tenax Therapeutics Inc (TENX)?
The closing price on Oct 2, 2026 was $1.98. Our model-based fair value is $3.11, about +57% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tenax Therapeutics Inc right now?
The large discount to fair value meets weak quality (25/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($2.06). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.06 to $3.89) leaves room in how you read the outcome.
Key figures of Tenax Therapeutics Inc
How large is the market capitalisation of Tenax Therapeutics Inc (TENX)?
The market capitalisation of Tenax Therapeutics Inc is $325M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Tenax Therapeutics Inc (TENX)?
Earnings per share at Tenax Therapeutics Inc are $−1.41. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Tenax Therapeutics Inc (TENX)?
The return on equity (ROE) of Tenax Therapeutics Inc is −51.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tenax Therapeutics Inc (TENX)?
On an EBIT basis the return on assets of Tenax Therapeutics Inc is −203% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Tenax Therapeutics Inc (TENX) generate?
The free cash flow of Tenax Therapeutics Inc is −$35.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Tenax Therapeutics Inc (TENX) hold?
Tenax Therapeutics Inc holds more cash than debt, $97.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Tenax Therapeutics Inc in the live analysis
One click puts Tenax Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026